江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20200514 | --- | --- | --- | |-------------------------|-------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 □其他 | | | 参与单位名称及 人员姓名 | | 睿远基金 朱璘；睿远基金 汤国柱 | | | | | | 时间 | 2020 年 5 月 14 | 日 10:00-12:00 | | 地点 | 公司本部 | | | 上市公司接待人 员姓名 | | 董事长 包建华 ；董事会秘书 黄晓东；证券事务代表 彭云 | | 投资者关系活动 | | 一、介绍公司基本情况： | | 主要内容介绍 | | 基本情况：公司以特色抗菌原料药及其中间体的研发、 | | | | 生产和 ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20180117 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | 华鑫证券 杜永宏 | | | 人员姓名 | 华鑫证券 汤锋 | | | 时间 | 2018 年 1 月 17 | 日 14:30-17:00 | | | | | | 地点 | 公司本部 | | | 上市公司接待人 员姓名 | 董事会秘书 黄晓东 | | | 投资者关系活动 | | 首先，董事会秘书黄晓东介绍了公司的基本情况，以及 | | 主要内容介绍 | 未来的发展规划。 | | | | 公司基本情况： | 公司创建于 2002 ...

承诺 书 江西富祥药业股份有限公司: | --- | --- | |-----------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | 本人(公司)将对你公司进行调研(或采访等),根据有关规定作出如下承 | | 诺: | | | | (一)本人(公司)承诺在调研(或采访等)过程中不故意打探公司未公开 | | | 重大信息,未经公司许可,不与公司指定人员以外的人员进行沟通或问询; | | | (二)本人(公司)承诺不泄漏在调研(或采访等)过程中无意中获取的公 | | | 司未公开重大信息,不利用所获取的未公开重大信息买卖公司证券或建议他人买 | | | 卖公司证券; (三)本人(公司)承诺在投资价值分析报告、新闻稿等文件中不使用本次 | | | 调研（或采访等）获取的公司未公开重大信息,除非公司同时披露该信息; | | | (四)本人(公司)承诺基于本次调研(或 ...

Group 1: Company Overview - Jiangxi Fuxiang Pharmaceutical Co., Ltd. is a significant player in the raw material drug industry, focusing on the production of carbapenem antibiotics and antiviral intermediates, with products sold in over 20 countries and regions [3][4] - The company has six production bases in Jiangxi, Shandong, and Liaoning, along with two R&D institutions and one import-export company in Zhejiang [3] - Fuxiang is recognized as a national high-tech enterprise and has received various certifications, including from the FDA and PMDA [3][4] Group 2: Financial Performance - The company has maintained continuous profitability and revenue growth since its establishment, with a nearly 17% increase in sales for its Agatroban injection over the past three years [5][6] - In the first half of the year, the net profit after deducting non-recurring gains and losses increased year-on-year, driven by stable market demand for its main products [4][5] Group 3: Future Development Plans - Fuxiang plans to focus on its core business of antibiotics and antiviral drugs, exploring industry chain extensions to ensure sustained healthy growth [4][7] - The company is set to issue up to 1,004.15 million yuan in new shares to fund the construction of its biological pharmaceutical project and production of intermediates [8] Group 4: Product and Market Strategy - The company is the sole supplier of certain products in the market, such as the Shubatan series, and is one of the main manufacturers of the Tazobactam series in China [4][7] - Fuxiang is actively expanding its product line and enhancing its quality management systems to capture more market opportunities [5][6] Group 5: Investor Interaction and Feedback - During the investor interaction, the company emphasized its commitment to quality control and the importance of maintaining stable relationships with high-quality clients [6][7] - The company is also addressing the challenges posed by rising raw material prices by improving efficiency and exploring potential price adjustments [6][8]

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20201117 | --- | --- | --- | --- | |----------------|-----------------------------|-------|-----------------------------------------------------| | | √ 特定对象调研 □分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | 类别 | □ 新闻发布会 □路演活动 | | | | | √ 现场参观 □其他 | | | | 参与单位名称及 | | | 常州市新发展实业股份有限公司 苏文权、陈爱军 | | 人员姓名 | | | 广东天创私募证券投资基金管理有限公司 陈山林、欧阳宇 | | | 峻、王慧星 | | | | | | | 国新央企运营投资基金 吕致远、罗番 | | | 杭州涌源投资有限公司 罗华锋 | | | | | 恒泰证券股份有限公司 管宣 | | | | | | | 华宝（上海）股权投资基金管理有限公司 董书成 | | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20210902 | --- | --- | --- | |----------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20220119 | --- | --- | --- | |----------------|---------------------------------------|-------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 √ | 其他（电话会议） | | 参与单位名称及 | | 西南证券、华安基金、易方达基金、长城基金、中银基金、华 | | 人员姓名 | | 商基金、万家基金、博时基金、东方阿尔法、民生加银、华夏 基金、交银施罗德、上海汐泰投资。（以上排名不分先后） | | 时间 | 2022 年 1 月 18 日 | | | 地点 | 线上交流 | | | ...

Financial Performance - The company's revenue for Q3 2022 was CNY 401,061,621.11, representing a 38.23% increase year-over-year[5] - The net profit attributable to shareholders decreased by 93.25% to CNY 587,851.61 for the same period[5] - The net profit after deducting non-recurring gains and losses was CNY -2,600,243.66, a decline of 154.23%[5] - Total revenue for the first nine months of 2022 was CNY 999,139,110.11, an increase of 37.61% compared to CNY 726,088,446.13 in the same period of 2021, primarily due to rising raw material costs and increased costs from new product launches[10] - Net profit attributable to shareholders of the parent company decreased by 71.50% to CNY 45,901,162.55 from CNY 161,074,494.65 year-on-year, mainly due to a decline in total profit[10] - Total profit for the first nine months of 2022 was CNY 43,823,031.50, down 75.58% from CNY 179,452,494.13 in the previous year, attributed to increased raw material prices and higher operating costs[10] - The company reported a net profit of CNY 38,248,045.61 for the period, compared to a net profit of CNY 162,105,922.33 in the same period last year, reflecting a significant decline[22] - The net profit for Q3 2022 was CNY 27,591,333.08, a decrease of 82.4% compared to CNY 156,795,317.53 in Q3 2021[23] - Operating profit for Q3 2022 was CNY 44,797,754.09, down from CNY 180,622,798.01 in the same period last year[23] - The total profit for Q3 2022 was CNY 43,823,031.50, a decline of 75.6% from CNY 179,452,494.13 in Q3 2021[23] Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline of 96.37%, amounting to CNY 3,901,885.10[5] - Cash flow from operating activities decreased by 96.37% to CNY 3,901,885.10 from CNY 107,448,534.77, primarily due to increased payments for raw materials[10] - The company’s cash and cash equivalents decreased by 97.81% to -CNY 114,530,977.73 from -CNY 57,900,344.47, reflecting the impact of operating, investing, and financing activities[10] - Cash and cash equivalents at the end of Q3 2022 were CNY 1,069,410,810.42, down from CNY 1,438,855,984.20 at the end of Q3 2021[27] - The company reported a total cash inflow from operating activities of CNY 888,534,437.89 in Q3 2022, compared to CNY 870,729,162.01 in Q3 2021[26] - The net cash flow from investing activities for Q3 2022 was -CNY 440,605,240.03, slightly improved from -CNY 466,084,407.56 in Q3 2021[27] - The company incurred a total cash outflow from financing activities of CNY 827,786,148.91 in Q3 2022, compared to CNY 522,746,615.07 in Q3 2021[27] Assets and Liabilities - The total assets increased by 8.93% to CNY 5,096,103,187.34 compared to the end of the previous year[5] - Inventory increased by 32.24% to CNY 550,318,349.31 due to rising raw material costs and new product launches[9] - Long-term borrowings rose by 182.97% to CNY 998,872,000.00, indicating increased financing activities[9] - Total liabilities rose to CNY 2,218,871,787.29, up 25.6% from CNY 1,767,183,937.38 in the previous period[20] - Non-current assets totaled CNY 2,799,275,991.58, an increase of 18.2% from CNY 2,366,935,280.24 at the beginning of the year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,695, with no preferred shareholders[12] - The largest shareholder, Bao Jianhua, holds 20.88% of the shares, amounting to 114,815,808 shares, with 86,111,856 shares pledged[12] Operational Performance - Total operating revenue for the period reached CNY 1,232,211,008.36, an increase of 15.6% compared to CNY 1,065,981,273.35 in the previous period[22] - Total operating costs amounted to CNY 1,193,962,962.75, up 32.1% from CNY 903,875,351.02 in the prior period[22] - Gross profit margin decreased to approximately 3.1% from the previous period, indicating increased cost pressures[22] - Research and development expenses were CNY 55,798,555.09, representing an increase of 6.3% from CNY 52,296,089.08 in the previous period[22] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[22] Foreign Exchange Impact - The company reported a significant increase in financial expenses, with a change of -373.87% to -CNY 9,825,215.98, mainly due to increased foreign exchange gains from USD fluctuations[10] - The company experienced a foreign exchange impact of CNY 8,958,526.11 on cash and cash equivalents in Q3 2022[27]

Financial Performance - The company's revenue for Q1 2022 was CNY 402,333,468.40, representing a 1.82% increase compared to CNY 395,130,083.80 in the same period last year[7]. - Net profit attributable to shareholders decreased by 62.39% to CNY 27,950,530.66 from CNY 74,308,610.16 year-on-year[7]. - Basic earnings per share dropped by 64.29% to CNY 0.05 from CNY 0.14 in the same period last year[7]. - The company reported a 68.05% decrease in total profit due to rising raw material prices and increased operating costs[27]. - The decline in performance was primarily due to rising raw material prices, leading to a significant drop in overall gross margin[39]. - Net profit for Q1 2022 was CNY 23,281,932.07, a decrease of 68.5% compared to CNY 74,164,561.86 in Q1 2021[57]. Cash Flow - The net cash flow from operating activities was negative at CNY -48,959,708.08, a decrease of 235.79% compared to CNY 36,055,298.94 in the previous year[7]. - The company's cash flow from operating activities was negatively impacted, resulting in a net cash flow of CNY -48,959,708.08[61]. - The cash inflow from operating activities was CNY 284,729,838.49, an increase from CNY 235,086,088.28 in the previous year, representing a growth of approximately 21%[61]. - The cash inflow from investment activities was CNY 12,222,336.94, while the cash outflow was CNY 221,533,796.46, resulting in a net cash outflow of CNY -209,311,459.52[62]. - The cash inflow from financing activities was CNY 606,847,041.00, an increase from CNY 347,000,000.00 in the previous year, marking a growth of approximately 75%[62]. - The net cash flow from financing activities was CNY 292,333,453.01, compared to CNY 142,609,540.58 in the same period last year, indicating a significant increase[62]. Assets and Liabilities - Total assets increased by 5.88% to CNY 4,953,639,415.57 from CNY 4,678,491,173.43 at the end of the previous year[7]. - Total liabilities rose to CNY 2,085,861,950.57 in Q1 2022, compared to CNY 1,767,183,937.38 in Q1 2021, marking an increase of 18.0%[54]. - The total non-current assets amounted to CNY 2,523,355,287.47 in Q1 2022, an increase from CNY 2,366,935,280.24 in Q1 2021, representing a growth of 6.6%[55]. Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 47,680[33]. - The largest shareholder, Bao Jianhua, holds 20.88% of the shares, with 86,111,856 shares pledged[33]. - The company repurchased a total of 11,355,900 shares, accounting for 2.06% of the total share capital, with a total payment of 174,830,966 RMB[34]. Investments and Projects - The company’s investment income rose by 149.66% year-on-year, reflecting improved performance from investments[26]. - The company is actively developing lithium battery electrolyte additive projects to meet the growing market demand, ensuring stable raw material supply[44]. - The company has signed contracts for CDMO business with a total contract amount of RMB 35.11 million, including RMB 20.9 million for the production of the intermediate for Parovide[43]. - In 2022, the company expects to engage in related transactions with Lingfu Pharmaceutical Research Institute amounting to RMB 60 million, with a potential adjustment based on actual execution[41]. Operational Insights - The company experienced a 30.64% increase in accounts receivable compared to the beginning of the period, attributed to increased credit sales[14]. - Long-term borrowings increased by 61.76% compared to the beginning of the period, indicating a rise in financing activities[21]. - The company is in the process of ramping up production capacity for new projects, which has increased fixed asset depreciation[39]. - The company implemented an employee stock ownership plan in 2021, resulting in higher management expense amortization[39]. - The company plans to strengthen its core business and invest in new business formats, focusing on talent development and project construction[39]. - The company focuses on the integration of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations to enhance its core competitiveness and product value[40]. Research and Development - Research and development expenses for Q1 2022 were CNY 16,774,533.75, a decrease of 11.9% from CNY 18,910,244.93 in Q1 2021[57].

Financial Performance - The net profit attributable to shareholders decreased significantly compared to the previous year, primarily due to rising raw material prices and a decline in sales volume and prices of certain products, with investment losses recognized from a partnership affected by environmental policies[7]. - The company will not distribute cash dividends or issue bonus shares for the reporting period[21]. - The company's operating revenue for 2021 was ¥1,429,542,874.53, a decrease of 4.25% compared to ¥1,492,952,990.67 in 2020[38]. - The net profit attributable to shareholders in 2021 was ¥48,830,662.43, representing a significant decline of 84.71% from ¥319,300,200.51 in 2020[38]. - The net profit after deducting non-recurring gains and losses was ¥106,440,849.54, down 62.89% from ¥286,829,965.20 in the previous year[38]. - The net cash flow from operating activities decreased by 81.09% to ¥72,321,556.16 from ¥382,350,651.43 in 2020[38]. - The total assets at the end of 2021 increased by 15.64% to ¥4,678,491,173.43 compared to ¥4,045,665,857.13 at the end of 2020[38]. - The net assets attributable to shareholders decreased by 4.23% to ¥2,880,206,760.70 from ¥3,007,345,500.94 in 2020[38]. - The basic earnings per share for 2021 was ¥0.09, a decrease of 87.14% from ¥0.70 in 2020[38]. - The diluted earnings per share was also ¥0.09, down 86.96% from ¥0.69 in the previous year[39]. - The company reported a net profit of ¥-112,243,832.22 in Q4 2021, contrasting with profits in the first three quarters[41]. - The company received government subsidies amounting to ¥28,528,987.57 in 2021, down from ¥45,705,604.74 in 2020[43]. Market Expansion and Business Strategy - The company plans to strengthen existing businesses, expand market share, and enhance its competitive edge through increased R&D investment and the development of new products[10]. - The company is actively extending its business into CDMO, new energy, and new materials sectors to improve long-term profitability and risk resistance[11]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 30% increase in market share by 2023[32]. - Fushine Pharmaceutical is considering strategic acquisitions to enhance its product portfolio, with a budget of RMB 500 million allocated for potential deals in 2022[32]. - The company is positioned to benefit from the growing global demand for new drug research and development, particularly in the Asia-Pacific region[71]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[171]. - The company plans to accelerate its CDMO business development, with expected related transactions with Lingfu Pharmaceutical Research Institute amounting to RMB 60 million in 2022[142]. - The company is actively developing lithium battery electrolyte additive projects to capitalize on the growing demand in the lithium battery industry[143]. Research and Development - The company acknowledges the long R&D cycles in the pharmaceutical industry and will continue to invest in research while conducting thorough market studies[17]. - R&D investment increased by 25% in 2021, totaling RMB 150 million, aimed at enhancing product development and innovation[32]. - The R&D team consists of 301 members, accounting for 16.28% of total employees, supporting the company's innovation and development efforts[77][78]. - The company is investing heavily in R&D, with an allocation of 100 million RMB for the development of new pharmaceutical technologies in 2022[178]. - Research and development expenses amounted to 78,511,845.69 yuan, which is 5.49% of the operating revenue, showing an increase from 5.19% in 2020[106]. Environmental and Compliance Initiatives - The company emphasizes the importance of environmental protection and has increased investments in pollution control to comply with stricter regulations[15]. - The company is committed to compliance governance to enhance its competitive edge and ensure sustainable development[147]. - Safety production remains a priority, with ongoing training and inspections to ensure compliance and minimize risks[146]. Corporate Governance and Management - The company emphasizes its commitment to improving corporate governance and investor relations, ensuring compliance with all regulatory requirements[154]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure[157]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[160]. - The total remuneration for key management personnel was reported at 1,337,703 RMB, indicating a structured approach to executive remuneration[166]. - The company has a well-structured organizational framework, with independent operation of its general meeting, board of directors, and supervisory board[162]. Financial Outlook and Projections - Future guidance indicates a projected revenue growth of 20% for 2022, driven by new product launches and market expansion efforts[32]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 12%[151]. - The company aims to enhance its pharmaceutical supply chain by expanding production of new enzyme inhibitors and high-efficiency antibiotics, with a focus on increasing product value and core competitiveness[140]. Shareholder Returns and Capital Management - The company has repurchased a total of 11,355,900 shares, accounting for 2.06% of total share capital, with a total expenditure of approximately ¥174.83 million[89]. - The company plans to retain cash for project investments to ensure stable cash flow and support long-term development strategies[200]. - The decision not to distribute profits is aligned with the company's development needs and investor return considerations[200]. - The company emphasizes reasonable returns to investors and will continue to adhere to profit distribution policies[200].